Tenet Healthcare price target raised to $250 from $200 at Raymond James

Raymond James analyst John Ransom raised the firm’s price target on Tenet Healthcare (THC) to $250 from $200 and keeps an Outperform rating on the shares. The firm said Q3 results exceeded expectations, as the company reported above-Street adjusted EBITDA. The quarter did benefit from a $38M out of period direct payment program, so the core beat was closer to roughly $23M all attributable to the hospital division, the analyst tells investors in a research note.